blog-icon

Clinical research blog

Explore our blog for insights into the big questions in precision medicine and clinical research.

From N-of-1 to N-of-many: What haplotype-matched ASOs mean for rare disease trials

A new study published in The American Journal of Human Genetics suggests that individualized genetic therapies could eventually treat larger groups of patients ...
Continue reading

What the FDA's new potency guidance means for rare disease gene therapy trials

On November 2, 2026, the FDA issued its final guidance, Potency Assurance for Cellular and Gene Therapy Products, outlining a risk-based approach to ensuring th...
Continue reading

FDA's new genome editing guidance: Why patient identification matters earlier in development

The FDA's draft guidance on individualized human genome editing products, issued on 27 October 2026, proposes a pathway that could allow a single biologics lice...
Continue reading

Population genomic screening is scaling. Is clinical trial infrastructure keeping up?

New findings presented at ASHG 2026 show how population genomic screening is identifying genetic risk at scale and changing preventive care. For sponsors develo...
Continue reading

What BEAM-301 reveals about the next challenge in precision medicine trials

Beam Therapeutics' early clinical results highlight the promise of mutation-specific therapies. But as treatments become more genetically targeted, they also ra...
Continue reading

FDA approves emcitate for MCT8 deficiency

On September 28, 2026, the FDA approved Emcitate (tiratricol) to treat peripheral thyrotoxicosis in patients with MCT8 deficiency, also known as Allan-Herndon-D...
Continue reading

AATD gene editing race hinges on patient identification

In September 2026, three in vivo gene editing programs reported progress against the same rare disease, aimed at the same mutation. On September 7, YolTech repo...
Continue reading

FDA approves first therapy for Sanfilippo Type A

On 17 September 2026, the FDA granted standard full approval to FAYUVI (rebisufligene etisparvovec-hopf), a single-dose intravenous AAV9 gene therapy from Ultra...
Continue reading

Podcast recap: Marleah Dean Kruzel on reframing hereditary cancer uncertainty

In the latest episode of The Genetics Podcast, Patrick sits down with Dr. Marleah Dean Kruzel, Professor of Communication at the University of South Florida. He...
Continue reading

FDA draft guidance expands single-trial effectiveness pathway

In June 2026, the FDA released a revised draft guidance, Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products, that clarif...
Continue reading